Search results

"Monsanto Research Corporation a subsidiary of Monsanto Company"--Cover. ; "Mound Laboratory, Miamisburg, Ohio, operated for United States Atomic Energy Commission, U.S. Government Contract Number AT 33-1-GEN-53." ; "Date: July 31, 1964 ; Issued: December 11, 1964." ; "MLM-1212 ; TID-4500 (32nd Ed.) ; UC-4 Chemistry." ; Includes bibliographical references (p. 13). ; U.S. Atomic Energy Commission Contract ; Mode of access: Internet.

This work shows the possibility of obtaining potassium sulfate by converting phosphogypsum and potassium carbotane by the reaction CaSO4 + K2CO3 → ↓ CaCO3 + K2SO4. The optimal conditions for this process are determined. It is shown that in an aqueous medium at a temperature of 20 °C, a stoichiometric ratio of the initial components, the rotation speed of the stirrer 200 rpm for 15-30 min, the degree of use of Ca2+ ions is 94-95 %. Potassium sulfate contained in the liquid phase is transferred into the solid phase by evaporation and subsequent crystallization.

The changes in soil potassium pools under intense cropping and fertilized with potash fertilizer are still little known to the soils of Paraná State. The effects of potassium fertilization and successive cropping on changes in K pools in different soils of Paraná, Brazil, were investigated in this study. Twelve soil samples, collected from the upper layer 0–0.20 m, were fertilized or not with K and subjected to six successive cropping (i.e., soybean, pearl millet, wheat, common beans, soybean and maize). All the crops were grown for 45 days, and at the end of the second, fourth and sixth cropping, the soil from each pot was sampled to determination of the total K, non-exchangeable K, exchangeable K and solution K. The result showed that the soil potassium pools varied widely. Total K concentration ranged from 547 to 15,563 mg kg–1 (4,714 mg kg–1, on average). On the average, structural K, non-exchangeable K, exchangeable K and solution K of the soils constituted 84.0, 11.3, 4.6 and 0.1% of the total K, respectively. Soils differ in the ability to supply potassium to the plants in the short to medium term, due to the wide range of parent material and the degree of soil weathering. When the soils were not fertilized with K, the successive cropping of plants resulted in a continuous process of depletion of non-exchangeable K and exchangeable K pools; however, this depletion was less pronounced in soils with higher potential buffer capacity of K. The concentrations of K non-exchangeable and exchangeable K were increased with the addition of potassium fertilizers, indicating the occurrence of K fixation in soil. After the second cropping, the soil exchangeable K levels remained constant with values of 141 and 36 mg kg–1, respectively, with and without the addition of K fertilizer, reflecting in establishing of a new dynamic equilibrium of K in the soil.</p>

The University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI), in collaboration with the Food and Drug Administration (FDA), conducted research and outreach to solicit input from the public, including medical specialists, to better understand the use of certain bulk drug substances nominated for use in compounding by outsourcing facilities under section 503B of the Federal Food, Drug, and Cosmetic Act (the Act). In particular, we were interested in how drugs compounded with these bulk drug substances were used historically, and how they are currently used in clinical practice. The research will assist the FDA in its development of a list of bulk drug substances that outsourcing facilities can use in compounding under section 503B of the Act. Research for each bulk drug substance included a systematic literature review, interviews with medical experts and a survey of healthcare practitioners. Our findings for the nominated substance, Potassium chloride, were summarized in this report. ; U.S. Food and Drug Administration clinical use of bulk drug substances nominated for inclusion on the 503B Bulks List Grant number: #U01FD005946

The University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI), in collaboration with the Food and Drug Administration (FDA), conducted research and outreach to solicit input from the public, including medical specialists, to better understand the use of certain bulk drug substances nominated for use in compounding by outsourcing facilities under section 503B of the Federal Food, Drug, and Cosmetic Act (the Act). In particular, we were interested in how drugs compounded with these bulk drug substances were used historically, and how they are currently used in clinical practice. The research will assist the FDA in its development of a list of bulk drug substances that outsourcing facilities can use in compounding under section 503B of the Act. Research for each bulk drug substance included a systematic literature review, interviews with medical experts and a survey of healthcare practitioners. Our findings for the nominated substance, Aluminum potassium sulfate, were summarized in this report. ; U.S. Food and Drug Administration clinical use of bulk drug substances nominated for inclusion on the 503B Bulks List Grant number: #U01FD005946

The University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI), in collaboration with the Food and Drug Administration (FDA), conducted research and outreach to solicit input from the public, including medical specialists, to better understand the use of certain bulk drug substances nominated for use in compounding by outsourcing facilities under section 503B of the Federal Food, Drug, and Cosmetic Act (the Act). In particular, we were interested in how drugs compounded with these bulk drug substances were used historically, and how they are currently used in clinical practice. The research will assist the FDA in its development of a list of bulk drug substances that outsourcing facilities can use in compounding under section 503B of the Act. Research for each bulk drug substance included a systematic literature review, interviews with medical experts and a survey of healthcare practitioners. Our findings for the nominated substance, Potassium phosphate monobasic/dibasic, were summarized in this report. ; U.S. Food and Drug Administration clinical use of bulk drug substances nominated for inclusion on the 503B Bulks List Grant number: #U01FD005946

The results of studying the composition and rheological properties of solutions after separation of glaserite, as well as the influence of technological parameters on the process of evaporation of mother liquors in the production of potassium sulfate by conversion of flotation potassium chloride with mirabilite of the Tumryuk deposit, are presented. The evaporation process proceeds most intensively at 120 °C. In this case, after 60 minutes, the volume of the evaporated solution is reduced by 50 %. An increase in the volume of evaporated moisture from 20 to 40 % contributes to an increase in the sludge yield from 11.8 to 22.9 %. The density of solutions increases with an increase in the volume of evaporated liquid, and the viscosity slightly decreases. During evaporation, the density increases from 1.298 g/cm3 when 20 % moisture is removed to 1.358 g/cm3 when 40 % moisture is evaporated at a temperature of 20 °C. In this case, the viscosity decreases from 2.072 to 2.007 mPa·s. It is shown that at a ratio of glaserite sodium sulfate to potassium chloride equal to 1 : 1, a temperature of 30 °C and process duration of 40 minutes, the degree of conversion reaches 86.65 % in terms of potassium.